Neurocrine Biosciences (NBIX) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $15.03B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Kyle W. Gano |
| IPO Date | 1996-05-23 | CAGR | 18.83% |
| Employees | 2,500 | Website | www.neurocrine.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 3.06% | Total Yield | 3.06% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $15.35B | P/E | 21.6 | Forward P/E | 12.53 | PEG | 0.74 |
| P/S | 0.64 | P/B | 0.54 | P/CF | 2.42 | P/FCF | 2.46 |
| Sales | $3.37B | Sales 1Y | 34.42% | Sales 3Y | 101.67% | Sales 5Y | 226.96% |
| EPS | $6.92 | EPS 1Y | 101.78% | EPS 3Y | 294.22% | EPS 5Y | 83.33% |
| Sales QoQ | 17.74% | EPS QoQ | -27.23% | Sales QoQ Avg | 8.95% | EPS QoQ Avg | 16.71% |
| Gross Margin | 97.97% | Operating Margin | 23.34% | Profit Margin | 20.91% | ROCE | 17.56% |
| ROA | 13% | ROE | 21% | Altman Z Score | 8.97 | Piotroski Score | 5 |
| Current Ratio | 1.87 | Quick Ratio | 1.75 | Cash Ratio | 0.38 | Op. CF Ratio | 0.16 |
| Debt/Equity | 0.1 | Debt/Assets | 0.07 | Lt Debt/Equity | 0.1 | Lt Debt/Cap. | 0.09 |
| Intrst Cov. | -271.52 | Inventory Turnover | 0.66 | Asset Turnover | 0.63 | Receivables Turnover | 3.8 |
| Enterprise Value | $15.35B | P/E Ratio | 21.6 |
| Forward P/E | 12.53 | PEG Ratio | 0.74 |
| P/S Ratio | 0.64 | P/B Ratio | 0.54 |
| P/CF Ratio | 2.42 | P/FCF Ratio | 2.46 |
| EPS | $6.92 | EPS Growth 1Y | 101.78% |
| EPS Growth 3Y | 294.22% | EPS Growth 5Y | 83.33% |
| Revenue Growth 1Y | 34.42% | Gross Margin | 0.98% |
| Operating Margin | 0.23% | Profit Margin | 0.21% |
| ROE | 0.21% | ROA | 0.13% |
| ROCE | 0.18% | Current Ratio | 1.87 |
| Quick Ratio | 1.75 | Cash Ratio | 0.38 |
| Debt/Equity | 0.1 | Interest Coverage | -271.52 |
| Altman Z Score | 8.97 | Piotroski Score | 5 |
Neurocrine Biosciences (NBIX) valuation & financials
Neurocrine Biosciences (NBIX) has a market capitalization of $15.03B and trades at a price-to-earnings ratio of 21.6. It operates in the Healthcare sector (Biotechnology).
Neurocrine Biosciences's revenue grew +34.4% over the last year.
Neurocrine Biosciences's next earnings report is scheduled for October 27, 2026 after market close; analysts estimate EPS of $2.59. Check the earnings calendar to see all companies reporting this week.
Neurocrine Biosciences (NBIX) — frequently asked questions
When does Neurocrine Biosciences (NBIX) report earnings next?
Neurocrine Biosciences is expected to report earnings on October 27, 2026 after market close. Analysts estimate EPS of $2.59.
What is Neurocrine Biosciences's market cap?
Neurocrine Biosciences (NBIX) has a market capitalization of $15.03B.
What is NBIX's P/E ratio?
Neurocrine Biosciences trades at a price-to-earnings ratio of 21.6, with trailing twelve-month EPS of $6.92.
How fast is Neurocrine Biosciences growing?
Neurocrine Biosciences's revenue grew +34.4% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)